Fig. 2From: Improved synthesis of [18F] fallypride and characterization of a Huntington’s disease mouse model, zQ175DN KI, using longitudinal PET imaging of D2/D3 receptorsTime activity curves of [18F] fallypride in striatum and cerebellum (reference region) at the age of 9 months (a) and 12 months (b). Data is presented as % of injected dose/cubic centimeter of tissue (%ID/cc) ± SDBack to article page